Catalyst Augmented Target Specific Polypeptide

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides a bioorthogonal catalytic system for targeted human therapy, specifically by engineering a catalytic unit where an abiotic transition metal (such as palladium) is stably complexed with a designed peptide. The peptide not only protects the highly reactive catalytic metal from inactivation or toxicity in biological environments, but also allows its fusion to a targeting molecule, such as a tumor-specific antibody or nanobody. As a result, the catalyst can be directed specifically to certain cell types, such as cancer cells, and used to localize or activate therapeutic reactions, including in situ activation of prodrugs at the disease site.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted activation of anticancer prodrugs at tumor sites, improving cancer treatment specificity and reducing systemic toxicity.
• Development of antibody- or nanobody-drug conjugates that include a catalytic component for localized drug synthesis or activation.
• Diagnostic imaging, by attaching the catalyst-peptide unit to molecules that recognize disease biomarkers and catalyze signal generation in situ.
• Treatment of other diseases with defined cell-surface markers (e.g. autoimmune, neurodegenerative disorders) by targeting disease-related cells for precise therapeutic intervention.
• Labeling or modifying specific proteins or cell types within a living organism for research or therapeutic purposes using bioorthogonal chemistry.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables highly precise targeting of therapeutic catalytic activity to disease sites, minimizing off-target effects and toxicity.
• Improves the stability and biocompatibility of transition metal catalysts in physiological conditions, overcoming previous limitations of rapid deactivation or toxicity.
• Allows for in situ conversion of harmless prodrugs to active drugs only at desired locations, increasing therapeutic efficacy and safety.
• Facilitates modular design; targeting molecules (antibodies, peptides, etc.) can be easily fused with the catalytic unit for customizable applications.
• Potential to overcome key shortcomings of antibody-drug conjugates, such as low drug loading and instability, by catalytic turnover at the target site.
• Applicable to a wide range of diseases where cell-specific targeting is possible, including cancers, autoimmune disorders, and neurological diseases.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to an improved targeted transition metal catalyst (TMC) suitable for human therapy.